+Vote!
Fool.com (Free subscription) | 7 hours ago
... HIV drugs like Gilead Sciences(Nasdaq: ) and Bristol-Myers Squibb's (NYSE: ) Atripla, or Abbott Labs' (NYSE: ) Kaletra, Johnson & Johnson will need to get Intelence approved to treat patients earlier in the disease progression. Those studies are currently under way.In the meantime, investors will have to be content with whatever low level of sales Intelence brings in -- Johnson & Johnson...
4Vote!
Pharmalot (Free subscription) | 11/24/2009
Prescriptions for both of Merck’s cholesterol pills - Vytorin and Zetia - fell last week, while scrips for Abbott Labs’ Niaspan rose following the results of the widely reported Arbiter clinical trial, according to SDI, a market research firm, Dow Jones reports. The Arbiter trial found that Niaspan helped reverse narrowing of the arteries in heart [...]
7Vote!
Gay South Florida (Free subscription) | 11/25/2009
... 9:00. Please mark your calendars now. This event is completely underwritten by the generosity of Abbott Labs, Walgreens Pharmacy and Georgies Alibi. Media sponsors include Hotspots Magazine, Jumponmarkslist.com, Latino Boys Magazine and Mack Planet. We have attached and included below the artwork we are using for this event and if you have any questions or would like to volunteer some time...
3Vote!
NewsInferno (Free subscription) | 11/23/2009
Meridia, Abbott Labs’ popular prescription weight loss medication, may be associated with a higher risk of heart-related side-effects, including heart attacks, strokes and death. Over the weekend, the U.S. Food & Drug Administration (FDA) issued a Meridia Early Communication, and said it was reviewing preliminary data from a recent study that indicated patients [...]
5Vote!
Fool.com (Free subscription) | 11/24/2009
... over the first quarter from drug-eluting stents sold by Johnson & Johnson, Boston Scientific, and Abbott Labs
6Vote!
Fool.com (Free subscription) | 11/23/2009
The Side Effect of Developing Obesity DrugsBy Brian Orelli 1 Abbott Labs' Meridia is supposed to make patients healthier by helping them lose weight, but it looks like it's having the in some patients.In a large 10,000-patient study, the obesity drug apparently increased the chance of a cardiovascular-related event, like heart attacks or strokes. The Food and Drug Administration said it's looking...
3Vote!
Boycott Novell (Free subscription) | 11/23/2009
... Real money is involved: The largest patent-case judgment is for $1.67 billion, being appealed by Abbott Labs in a case brought in the plaintiff-happy federal court in eastern Texas. Here is perspective on the pharmaceutical industry . The book ends with the perennial question of “would we have got where we are today without patents'” Dutfield points out that it almost goes without saying...
7Vote!
The Street (Free subscription) | 11/23/2009
WASHINGTON () -- Abbott Labs' weight-loss drug Meridia may cause a higher incident of heart-related adverse events, including heart attacks, strokes and death, than patients using a placebo, according to preliminary data flagged in an alert by the U.S. Food and Drug Administration late Friday. More from Adam Feuerstein The new, unexpected warning about a possibly serious side effect related...
